Viva Ventures Biotech Fund Completed $63M initial Closing for its USD Biotech Fund II
On March 31, 2021, Viva Ventures Biotech Fund announced its initial closing for its USD fund II. New LPs boarding on include several well-known and influential individual investors and family offices. They highly recognize Viva Ventures’ investment performance and expertise. Investing in the USD fund, they are willing to provide strategic support for the future fundraising and industrial resources for the development of portfolio companies. The total size of Viva Ventures Biotech Fund II is $100M. It has completed $63M in the initial closing.
Viva Ventures is one of the very few biotech VCs that have extensive expertise and industry know-how for early-stage investments.
Established in 2016, Viva Venture Fund I invested in 10 startups. Among the investments, four had exited successfully, including two exits through M&A and two through IPO. By the end of 2020, the TVPI of Fund I is more than 10X.
Viva Ventures Biotech Fund II will keep on investing global first-in-class, discovery-stage biotech startups with significant growth potential, and helping them grow from 0 to 1, from idea to NewCo.
Marketing and investor relations：Zhichunwang@vivaventuresbiotech.com
Viva Ventures Biotech Fund Website: www.vivaventuresbiotech.com